# A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

> **NCT04847440** · PHASE2 · TERMINATED · sponsor: **Antios Therapeutics, Inc** · enrollment: 40 (actual)

## Conditions studied

- Hepatitis B, Chronic
- Hepatitis D

## Interventions

- **DRUG:** ATI-2173
- **DRUG:** Viread
- **DRUG:** AB-729

## Key facts

- **NCT ID:** NCT04847440
- **Lead sponsor:** Antios Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-30
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Terminated by the Sponsor
- **Last updated:** 2022-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04847440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04847440, "A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04847440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*